AdenoAssociatedViral(AAV)VectorMarket|Trendsand Forecast(2035)
The Adeno Associated Viral Vector market is anticipated to grow at aCAGRofmorethan10% by 2035, claims Roots Analysis. Given their low immunogenicity, diversifiedtargetsandability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the developmentofvarioustherapiesforthetreatmentofchronicdiseasesandinfections.
RootsAnalysishasannouncedtheadditionof“AdenoAssociatedViralVectorMarket, 2022-2035”reporttoitslistofofferings.Thereportfeaturesanextensivestudyonthecurrent landscapeandthelikelyfuturepotentialofadeno-associatedviralvectormarketoverthenext decade.
The study also features an in-depth analysis, highlighting the capabilities of various stakeholdersengagedinthisdomain.Amongstotherelements,thereportfeatures:
▪ A general overview of the various types of viral and non-viral vectors. Itincludesadetailed discussion on structure and design, life cycle and applications of adeno-associated viral vectors. The chapter concludes with a discussion on the various advantages and challenges relatedtoadeno-associatedviralvectors.
▪ A detailed overview of the overall market landscape of adeno-associated viral vector-based therapies,includinginformationontheirphaseofdevelopment,keytherapeuticareas,typeof
gene / molecule targeted, type of therapy, type of gene delivery method used, route of administrationandspecialdrugdesignation(s)awarded.
▪ An overview of the current status of the market with respect to the players engaged in the manufacturing of adeno-associated viral vectors, featuring information on the year of establishment, company size, location of headquarters, type of product manufactured, location of manufacturing facilities, type of manufacturer, scale of operationandapplication area.
▪ An overview of the technologies offered / developed by the companies enagaged in this domain, including a detailed analysis based on the type of technology, scale of operation, application and most prominent players within this domain, in terms of number of technologies.
▪ Detailed profiles of marketed and late stage (phase II / IIIandabove)adeno-associatedviral vector based therapies, along with information on the development timeline of the therapy, current development status, mechanism of action, affiliated technology, patent portfolio, dosageandmanufacturingdetails,aswellasdetailsrelatedtothedevelopercompany.
▪ Tabulated profiles of players havingcapabilitytomanufactureadeno-associatedviralvectors (shortlisted basedonproprietarycriterion).Eachprofilefeaturesanoverviewofthecompany / organization, its financial performance (if available), vector manufacturing related capabilitiesandaninformedfutureoutlook.
▪ A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of adeno-associated viral vector, based across key geographical areas, featuring a four-dimensional bubble representation, which takes into consideration supplier strength,manufacturingstrength,servicestrengthandcompanysize.
▪ A detailed competitiveness analysis of adeno-associated viral vector platforms, taking into consideration the supplier strengthand key technology specifications, such as purpose of technology,scaleofoperationandapplicationarea(s).
▪ An in-depth analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target therapeutic area,geography,typeofsponsor,prominenttreatmentsitesandenrolledpatientpopulation.
▪ An analysis of recent collaborations and partnership agreements inked in this domain since 2017; it includes details of deals that were / are focused on the manufacturing of vectors, whichwereanalyzedonthebasisofyearofpartnership,typeofpartnership,therapeuticarea, typeofpartnerandregionaldistributionofpartnerships.
▪ An insightful analysisofthecompaniesthathavelikelihoodofestablishingpartnershipswith adeno-associated viral vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, therapeutic area and pipeline strength.
▪ An in-depth analysis of various patents that have been filed / granted for adeno-associated viral vector-based therapies since2017,basedonseveralrelevantparameters,suchastypeof patent, publication year, regional applicability, CPC symbols, emerging focus areas, leading industryplayers(intermsofthenumberofpatentsfiled/granted),andpatentvaluation.
▪ An analysis of the various start-ups engaged in the development of adeno-associated viral vectors-based therapies, based on relevant parameters, such as number of candidates in
discovery, preclinical and clinical phases of development, number of patents and number of partnershipsestablished.
▪ An insightful analysis, highlighting the various factors that need to be taken into consideration by adeno-associated viral vector manufacturerstofacilitatedecisionmakingto manufacture their respective productsin-houseorengagetheservicesofaCMO.Further,the analysis highlights all the key parameters that must be considered by players based on companysizes,whiletakingtheaforementioneddecision.
▪
▪
▪
▪
TypeofTherapy
GeneAugmentation
Immunotherapy
OtherTherapies
▪ TypeofGeneDeliveryMethodUsed
▪ Exvivo
▪ Invivo
▪ TargetTherapeuticArea
▪ GeneticDisorders
▪ HematologicalDisorders
▪ InfectiousDiseases
▪ MetabolicDisorders
▪ OphthalmicDisorders
▪ MuscleDisorders
▪ NeurologicalDisorders
▪ Others
▪ ScaleofOperation
▪ Preclinical
▪ Clinical
▪ Commercial
▪ ApplicationArea
▪ GeneTherapy
▪ CellTherapy
▪ Vaccines
▪ GeographicalRegions
▪ NorthAmerica
▪ Europe
▪ Asia-Pacific
▪ MENA
▪ LatinAmerica
▪ RestoftheWorld
Keycompaniescoveredinthereport
▪ AbeonaTherapeutics
▪ Aldevron
▪ OxfordBioMedica
▪ Sanofi
▪ WuXiAppTec
▪ Yposkesi